期刊
IMMUNOTHERAPY
卷 10, 期 16, 页码 1349-1360出版社
FUTURE MEDICINE LTD
DOI: 10.2217/imt-2018-0078
关键词
cancer immunology; cancer vaccines; DNA plasmid; gene therapy; immunotherapy; molecular immunology; nanoparticles; non-small-cell lung cancer; vaccine vectors
类别
资金
- American Cancer Society [98-277-10]
Aim: Lung cancer gene therapies require reagents to selectively transfect lung tumors after systemic administration. Materials & methods: We created a reagent called NSCLC-NP by attaching a peptide with binding affinity for lung cancer to polyamidoamine dendrimers. The positively charged dendrimers electrostatically bind negatively charged nucleic acids, inhibit endogenous nucleases and transfect cells targeted by the attached peptide. Results:In vitro, NSCLC-NP complexed to DNA plasmids bound and transfected three human lung cancer cell lines producing protein expression of the plasmid's gene. In vivo, systemically administered NSCLC-NP selectively transfected lung cancer cells growing in RAG1KO mice. Conclusion: The capability of NSCLC-NP to selectively transfect lung cancer allows its future use as a vehicle to implement human lung cancer gene therapy strategies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据